報價延遲最少15分鐘:2024/04/27 12:50 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
5 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.42/-4.40
|
|
企業價值
84.86M
|
| 資產負債 |
|
每股賬面淨值
0.41
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/04/27 12:50 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development,LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications. |